login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
COCRYSTAL PHARMA INC (COCP) Stock News
NASDAQ:COCP -
US19188J4094
-
Common Stock
1.5
USD
-0.07 (-4.46%)
Last: 8/29/2025, 8:14:06 PM
1.5
USD
0 (0%)
After Hours:
8/29/2025, 8:14:06 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
COCP Latest News, Press Relases and Analysis
All
Press Releases
16 days ago - By: The Motley Fool
Cocrystal Pharma Narrows Loss in Q2
16 days ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
a month ago - By: Benzinga
- Mentions:
OPK
ATEC
MBRX
BIO
...
12 Health Care Stocks Moving In Thursday's After-Market Session
3 months ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
4 months ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
a year ago - By: BusinessInsider
COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024
a year ago - By: InvestorPlace
COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024
a year ago - By: InvestorPlace
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024
5 months ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
6 months ago - By: Virtual Investor Conferences
- Mentions:
CGTX
AVCN.CA
NGEN.CA
FBLG
...
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
6 months ago - By: Virtual Investor Conferences
- Mentions:
CGTX
AVCN.CA
NGEN.CA
FBLG
...
Life Sciences Investor Forum Agenda Announced for March 13th
a year ago - By: InvestorPlace
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023
a year ago - By: BusinessInsider
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023
8 months ago - By: Benzinga
- Mentions:
SGMO
VSTM
TLSA
ONCO
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 months ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
a year ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
a year ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
a year ago - By: Cocrystal Pharma, Inc.
New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
a year ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
a year ago - By: Cocrystal Pharma, Inc.
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
a year ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
a year ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
2 years ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
2 years ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
2 years ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
2 years ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
2 years ago - By: Cocrystal Pharma, Inc.
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
Please enable JavaScript to continue using this application.